Holmium laser enucleation of the prostate: efficacy, safety and preoperative management in patients presenting with anticoagulation therapy

Marina Deuker1,2 · Jessica Rührup1 · Pierre I. Karakiewicz2 · Maria Welte1 · Luis A. Kluth1 · Severine Banek1 · Frederik C. Roos1 · Philipp Mandel1 · Felix K.-H. Chun1 · Andreas Becker1

Received: 27 March 2020 / Accepted: 19 May 2020 / Published online: 2 June 2020
© The Author(s) 2020

Abstract

Purpose We evaluated efficacy and safety profile of patients with anticoagulation therapy (AT) undergoing holmium laser enucleation of the prostate (HoLEP).

Methods Within our prospective institutional database (11/2017 to 11/2019), we analyzed functional outcomes and 30-day complication rates of HoLEP patients according to Clavien–Dindo classification (CLD), stratified according to specific AT vs. no AT. Further analyses consisted of uni- and multivariate logistic regression models (LRM) predicting complications.

Results Of 268 patients undergoing HoLEP, 104 (38.8%) received AT: 25.7% were treated with platelet aggregation inhibitors (PAI), 8.2% with new oral anticoagulants (NOAC) and 4.9% with AT-combinations or coumarins bridged with low molecular weight heparins (LMWH/comparison). Patients receiving AT were significantly more comorbid (p < 0.01). Pre- and postoperative maximal flow rates, residual void urine and IPSS at 3 months after surgery were invariably improved after HoLEP for patients with/without AT. Overall complication rate was 19.5% in patients with no AT vs. 26.1% vs. 27.3 vs. 46.2%, respectively, in patients with PAI, NOAC and LMWH/combination (p < 0.01). Major complications (CLD ≥ 3b) occurred in 6.1% of no AT patients vs. 4.3% vs. 4.5% vs. 0% in patients with PAI, NOAC and LMWH/combination, respectively (p < 0.01). In multivariate LRM, AT was not significantly associated with higher complication rates, whereas high ASA status (OR 2.2, p = 0.04), age (OR 1.04, p = 0.02) and biopical or incidental prostate cancer (OR 2.5, p = 0.01) represented independent risk factors.

Conclusion Despite higher overall complication rates in AT patients, major complications were not more frequent in AT patients. HoLEP is safe and effective in anticoagulated patients.

Keywords HoLEP · Anticoagulation · Complications · Bleeding · Transfusion · Clavien–Dindo classification

Introduction

Bladder outlet obstruction (BOO) represents a frequent condition in older men and its prevalence is increasing with higher age [1, 2]. Especially a rising proportion of patients with cardiovascular diseases require a consequent anticoagulation therapy (AT). Moreover, a rising amount of patients has a regular medication with new oral anticoagulants (NOAC) or with platelet aggregation inhibitors (PAI) [3–5].

For decades transurethral resection of the prostate (TURP) has been considered the gold standard endoscopic approach for subvesical desobstruction [6]. However, it is associated with bleeding complication rates in up to 33% in patients with AT [7]. Safer but equally effective techniques are warranted, such as the holmium laser enucleation of the prostate (HoLEP) [8]. HoLEP is associated with fewer bleeding complications and shorter hospitalization rate compared to TURP and open retropubic enucleation of the prostate [9–11]. Moreover, small cohort studies also suggested the safety and efficacy of HoLEP in patients with AT...
We herein report our institutional experience since implementation of HoLEP in 2017 regarding its safety and efficacy in anticoagulated patients. In contrast to older series that mainly included patients taking ASS or Coumarins, our study includes three different groups of AT (PAI, NOAC and low molecular weight heparins (LMWH)/combinations). We hypothesized that HoLEP can be performed safely and effectively in those patients.

Materials and methods

Study population

Within our prospective institutional database, 268 consecutive patients who underwent HoLEP for BOO between November 2017 and November 2019 were identified. Patients with urethral strictures were excluded. Patients were stratified into four groups depending on the kind of perioperative AT vs. no AT. Acetylsalicylic acid (ASS) and platelet aggregation inhibitors (PAI, such as clopidogrel) were grouped as PAI, the second group consisted of new oral anticoagulants (NOAC; such as dabigatran, a direct thrombin inhibitor, or oral direct factor Xa inhibitors, such as rivaroxaban or apixaban), patients with low molecular weight heparins (LMWH), or bridged with LMWH as substitution for Vitamin K antagonists (Coumarins) or any combination agents were registered among “LMWH/combination”.

Perioperative management of patients with AT

Patients, who took Coumarins, stopped taking the medication 10 days before HoLEP and were bridged with LMWH during the perioperative period. Patients taking NOAC, stopped taking medication 48 h before surgery without replacement; postoperatively they were treated with LMWH in semi-therapeutic scheme for 14 days. Patients on ASS did not pause ASS and patients with other PAI were either changed to ASS or temporarily paused the medication. All patients had an INR < 1.5 and at least 80,000 thrombocytes/µl at time of surgery. However, in agreement with the treating general physician or cardiologist, also other schemes were individually fitted in accordance with specific patient requirements.

All surgical procedures were performed with the Olympus, OES Pro Laser Resectoscope, a high power (120 W) holmium laser generator (MOSES Pulse 120H, Lumenis), a 550 nm laser fiber (Lumenis, Slim Line) and a morcellator (Versacut, Lumenis). Operations were performed in one-, two- or three-lobe technique. HoLEP was performed by three experienced senior HoLEP-surgeons. An overview of the individual surgical steps can be viewed online at GeSRU StepS (https://www.gesru.de/fuer-assistenzarzte/fortbildung/gesru-steps/steps-video/) as a surgical tutorial video.

Postoperative complications were recorded according to the Clavien–Dindo (CLD) classification system using a graduation from CLD I to CLD V [14]. Complications occurring within 30 days after the procedure were recorded as early complications. Major complications were defined as CLD equal or greater IIIb. The follow-up was scheduled by the use of systematic questionnaires that were sent to the patients prospectively after 4 weeks, 3 months and one year. Catheter status and—if applicable—uroflow and post-void residual urine were examined in all patients before discharge. Follow-up, including IPSS was available for 26% (n = 70).

Statistical analysis

Descriptive statistics included frequencies and proportions for categorical variables. Means, medians, and interquartile-ranges (IR) were reported for continuously coded variables. The Chi-square test was used to assess the statistical significance in proportions’ differences. The t test and Kruskal–Wallis test examined the statistical significance of means’ and medians’ differences. Multivariate logistic regression models (LRM) tested the effect of AT on complications.

In all statistical analyses, R software environment for statistical computing and graphics (version 3.6.1) was used. All tests were two-sided with a level of significance set at p < 0.05 (bold font in tables). Ethical approval was obtained from the local ethics committee at the University Hospital of Frankfurt. All included patients gave informed written consent.

Results

Descriptive characteristics of the study population

In our institutional database, we identified 268 eligible patients, who underwent HoLEP at the University Hospital Frankfurt from November 2017 to November 2019. Of those, 104 patients (38.8%) were treated with AT. 69 patients (25.7% of the total cohort) were treated with PAI (among those were 66 patients with ASS-monotherapy) vs. 22 patients (8.2%) received NOAC vs. 13 patients (4.9%) with LMWH/combination (Table 1). Patients with AT were significantly older and showed more comorbidities (higher ASA status, p < 0.01). Prostate volume measured by TRUS (median: 79 vs. 65 vs. 80 vs. 60 ml) and PSA (median: 5.3
vs. 4.2 vs. 4.8 vs. 3.9 ng/ml) did not differ significantly between the subgroups.

**Perioperative outcomes**

Perioperative outcomes did not show major differences according to AT (Table 1). Catheter time (median 2 days in all subgroups, \( p = 0.07 \)), operative time (85–90 min, \( p = 0.2 \)) and velocity of tissue retrieval (operative time divided by enucleation volume: 0.5–0.7 g/min, \( p = 0.08 \)), as well as the incidence of prostate carcinoma did not show statistically significant differences. Conversely, the mean enucleation volume was significantly higher in no AT patients (\( p = 0.04 \)).

**Postoperative outcomes**

Preoperative and postoperative rates of maximal flow in uroflowmetry, residual void urine, number of patients with transurethral catheter at discharge and IPSS (International prostate symptoms score) at 3 months after surgery were invariably improved after HoLEP in each AT group (Fig. 1a–d). Due to sample size limitations, a statistically significant effect could not consistently be confirmed in NOAC and LMWH/combination patients in each subanalysis.

**Complication rates according to Clavien–Dindo classification**

Complication rates were assessed according to CLD classification system [15] (Table 1). Significant differences were recorded for overall early (30 days) complication rates with 19.5% in no AT patients vs. 26.1% vs. 27.3 vs. 46.2%, respectively, in PAI, NOAC and LMWH/combination patients (\( p < 0.01 \)).

In stratified analyses according to minor vs. major complications, minor complications were significantly more frequent in patients with AT compared to patients with no AT.

---

**Table 1** Preoperative and perioperative characteristics of 268 HoLEP patients stratified according to comedication with anticoagulative therapy (AT)

| Variable                   | Cat/Stat | Overall, \( n = 268 \) (%) | No AT, \( n = 164 \) (61.2) | PAI, \( n = 69 \) (25.7) | NOAC, \( n = 22 \) (8.2) | LMWH/comb., \( n = 13 \) (4.9) | \( p \) value |
|----------------------------|----------|-----------------------------|-----------------------------|------------------------|------------------------|--------------------------|------------|
| **Preoperative**           |          |                             |                             |                        |                        |                          |            |
| Age (years)                | Median (IQR) | 70 (63–76)                  | 67.5 (61–74)                | 73 (67–78)             | 73.5 (65–78)            | 74 (71–79)               | <0.01      |
|                           | Mean (STE)  | 69.5 (0.6)                  | 67.5 (0.674)                | 72.4 (0.916)           | 72.6 (1.541)           | 73.9 (1.603)             |            |
| PSA (ng/ml)                | Median (IQR) | 4.9 (2.8–8.6)               | 5.3 (2.8–9.4)               | 4.2 (2.4–8.2)          | 4.8 (2.1–6.3)          | 3.9 (3.6–4.9)           | 0.2        |
|                           | Mean (SD)  | 8.5 (1.1)                   | 9.6 (1.241)                 | 7.9 (1.846)            | 5 (0.728)              | 4.3 (0.801)              | <0.01      |
| TRUS (ml)                  | Median (IQR) | 73 (54–100)                 | 79 (55–104)                 | 65 (50–98.5)           | 80 (57–88.8)           | 60 (50–95)              | 0.06       |
|                           | Mean (SD)  | 82.7 (3.186)                | 87.3 (3.353)                | 76.1 (4.862)           | 75.6 (5.04)            | 72.6 (9.239)           | 0.06       |
| ASA I                      |           | 17 (6.3)                    | 15 (9.1)                    | 2 (2.9)                | 0 (0)                  | 0 (0)                   | <0.01      |
| ASA II                     |           | 147 (54.9)                  | 122 (74.4)                  | 21 (30.4)              | 4 (18.2)               | 0 (0)                   |            |
| ASA III                    |           | 101 (37.7)                  | 26 (15.9)                   | 45 (65.2)              | 17 (77.3)              | 13 (100)               |            |
| **Perioperative**          |          |                             |                             |                        |                        |                          |            |
| Catheter time (days)       | Median (IQR) | 2 (2–2)                    | 2 (2–3)                     | 2 (2–3)                | 2 (2–2)                | 2 (2–2)                | 0.07       |
|                           | Mean (SD)  | 2.2 (0.04)                  | 2.2 (0.044)                 | 2.4 (0.118)            | 2.2 (0.146)            | 2 (0)                | 0.2        |
| Enucleation volume (g)     | Median (IQR) | 51.3 (29–84)                | 56.5 (32.2–86.8)            | 45.5 (23.2–64.8)       | 46 (29.4–65.8)         | 39 (33.7–53.9)         | 0.04       |
|                           | Mean (SD)  | 61.04 (3.506)               | 66.4 (3.797)                | 52.2 (4.522)           | 56 (8.789)             | 48.8 (9.71)            | 0.02       |
| Operative time (min)       | Median (IQR) | 87.5 (60–120)               | 90 (61.8–120)               | 85 (62–120)            | 74 (60–138.2)          | 85 (53–105)           | 0.2        |
|                           | Mean (SD)  | 98.37 (3.08)                | 100.4 (3.907)               | 93.2 (4.671)           | 108.3 (15.726)         | 83.4 (11.058)          | 0.2        |
| Velocity of tissue retrieval (g/min) | Median (IQR) | 0.6 (0.3–0.9)               | 0.7 (0.4–0.9)               | 0.5 (0.3–0.8)          | 0.6 (0.3–0.9)          | 0.6 (0.4–1)            | 0.08       |
|                           | Mean (SD)  | 0.7 (0.03)                  | 0.7 (0.032)                 | 0.6 (0.045)            | 0.6 (0.088)            | 0.7 (0.124)            | 0.05       |
| Prostate carcinoma         | No        | 221 (82.5)                  | 139 (84.8)                  | 55 (79.7)              | 16 (72.7)              | 11 (84.6)             | 0.9        |
|                           | Incidental | 29 (10.8)                   | 15 (9.1)                    | 9 (13.0)               | 5 (22.7)               | 0 (0)                |            |
|                           | Biopctal   | 14 (5.2)                    | 7 (4.3)                     | 4 (5.8)               | 1 (4.5)               | 2 (15.4)             |            |

PAI platelet aggregation inhibitors, NOAC new oral anticoagulants, LMWH/comb. low molecular weight heparins or combination of AT, IQR interquartile range, SD standard deviation, TRUS transurethral prostate volume, ASA American Society of Anesthesiologists’ score
In contrast, the rate of major complications was not higher in patients receiving AT (6.1% of no AT patients vs. 4.3% vs. 4.5 vs. 0% of, respectively, PAI, NOAC and LMWH/combination patients, \( p < 0.01 \)).

**Logistic regression model predicting complication rates**

An exploratory univariate logistic regression model analyzed early complication rates according to AT, ASA status, age, operative time, bioplastic or incidental finding of prostate carcinoma (PCa) and prostate enucleation volume. Perioperative treatment with LMWH/combination (odds ratio [OR] 3.5, \( p = 0.03 \)), high ASA status (OR 2.6, \( p < 0.01 \)), age (OR 1.1, \( p < 0.01 \)) and bioplastic/incidental PCa (OR 2.9, \( p < 0.01 \)) were identified as univariate predictors of complications (Table 2). Conversely, in multivariate analyses adjusted for the given risk factors, AT was no longer significantly associated with higher complication rates, whereas high ASA status (OR 2.2, \( p = 0.04 \)), age (OR 1.04, \( p = 0.02 \)) and bioplastic/incidental PCa (OR 2.5, \( p = 0.01 \)) were confirmed as independent predictors of overall complications (Table 3).

**Discussion**

We reported our institutional experience regarding safety and efficacy of HoLEP in anticoagulated patients. Our analyses yielded several important observations.

First, AT therapy is widely used in candidates for surgical desobstruction for BOO. More than one third (38.8%) of BPH patients undergoing HoLEP were treated with AT therapy perioperatively. 25.7% of AT patients received PAI, 8.2% received NOAC (8.2%) and 4.9% LMWH/combination. AT patients were older and showed a higher burden of multimorbid conditions (high ASA status). With an aging population and widely available medical care on a high level in western countries more and more patients with polypharmaceutical therapy (AT). \(^{a}\) median is reported. PAI platelet aggregation inhibitors, NOACs new oral anticoagulants, LMWH/comb. low molecular weight heparins or combination of AT
the outcome of 2,178 patients (of whom 245 either took NOACs or Coumarins), analyzed by Becker et al. [18] in 2019, also reported a higher overall complication rate in patients taking AT. However, they did not classify according to Clavien–Dindo classification. Moreover, Zheng et al. [19] conducted a systematic meta analysis of overall nine studies analyzing the impact of AT on perioperative outcomes after HoLEP. They also found a significantly higher complication rate (including blood transfusion, bladder tamponade, urinary retention) in patients taking AT.

Various large series on HoLEP have reported its superiority over TURP with special regard to a lower risk of bleeding complications [20–22]. A potential explanation for the superior risk profile of HoLEP is, that prostatic vessels are dissected and coagulated only once during the enucleation process. However, considerably less detail is available regarding HoLEP and the perioperative use of AT [13, 23, 24] with most of the studies addressing only transfusion rates. In our study cohort, only one patient (0.4% of the study cohort/ 1% of AT patients) required a blood transfusion. This patient belonged to the LMWH/combination group (Coumarin, bridged with LMWH). In comparison to our very low transfusion rate, transfusion rates in previous studies had a vast range between 0% and 14.7% for patients taking AT: the largest reported series of HoLEP in AT patients (n = 116 patients with AT) by El Tayeb et al. [23] reported generally higher transfusion rates compared to the current series. However, their transfusion rates did not differ according to AT vs. no AT status (3.5 vs. 1.6%, p = 0.13). One smaller study (n = 52) by Bishop et al. [13] showed a significant higher transfusion rate in AT patients (7.7 vs 0%, p = 0.03). Another two institutional studies reported no transfusion (n = 39) [24] and up to 14.7% (n = 83) according to specific AT agents [12].

Neuville et al. stated a significantly longer length of stay and longer length of bladder irrigation in patients

| Variable | Cat/Stat | Overall, n=268 (%) | No AT, n=164 (61.2) | PAI, n=69 (25.7) | NOAC, n=22 (8.2) | LMWH/comb., n=13 (4.9) | p value |
|----------|---------|-------------------|---------------------|----------------|----------------|-----------------|---------|
| 30 days-complication rates | No complication | 206 (76.9) | 132 (80.5) | 51 (73.9) | 16 (72.7) | 7 (53.8) | <0.01 |
| CLD-I | 25 (9.3) | 13 (7.9) | 7 (10.1) | 3 (13.6) | 2 (15.4) | |
| CLD-IP | 15 (5.6) | 5 (3) | 6 (8.7) | 2 (9.1) | 2 (15.4) | |
| Transfusion | 1 (0.4) | 0 (0) | 0 (0) | 0 (0) | 1 (7.7) | |
| CLD-IIIa | 7 (2.6) | 4 (2.4) | 2 (2.9) | 0 (0) | 1 (7.7) | |
| CLD-IIIb | 13 (4.9) | 9 (5.5) | 3 (4.3) | 1 (4.5) | 0 (0) | |
| CLD-IV/V | 1 (0.4) | 1 (0.6) | 0 (0) | 0 (0) | 0 (0) | |
| Minor vs. major (CLD ≥ IIIb) Complication | No | 206 (76.9) | 132 (80.5) | 51 (73.9) | 16 (72.7) | 7 (53.8) | <0.01 |
| Minor | 48 (17.9) | 22 (13.4) | 15 (21.7) | 5 (22.7) | 6 (46.2) | |
| Major | 14 (5.2) | 10 (6.1) | 3 (4.3) | 1 (4.5) | 0 (0) | |

PAI platelet aggregation inhibitors, NOAC new oral anticoagulants, LMWH/comb. low molecular weight heparins or combination of AT, SPC suprapubic catheter

*Other than transfusion
taking AT, while patients taking PAI did not show significant differences to the no AT cohort. Only three studies reporting reoperation rates are currently available: Tyson et al. [24] reported on a staged procedure due to obscured vision by hematuria in 2/39 (5.1%) patients with AT as opposed to 5/37 (13.5%) patients without AT. Elzayat et al. [12] reported reoperation rates in 3.6% (n = 3/83) of AT patients due to bleeding refractory to transfusion and El Tayeb et al. [23] reported reoperation rates in 1.9% (2/116) of AT patients for clot removal. Those results are in line with our observed reoperation rates in AT patients (0–4.5%). It is of note that our study is the second largest out of three studies to report differentiated complication rates according to the Clavien–Dindo classification of complications.

Furthermore, we performed logistic regression models predicting complication rates and found AT to be univariately associated with higher complication rates (OR 3.5, p = 0.03 for LMWH/combination). Nevertheless, also high ASA status (OR 2.6, p < 0.01), age (OR 1.1, p < 0.01), and prostate carcinoma (OR 2.9, p < 0.01) were associated with univariably higher complication rates. Moreover, after adjusting for high ASA status and higher age, that were significantly more prevalent within AT patients, the predictive effect of complications disappeared for AT. Thus, it can be concluded that HoLEP can safely be performed in AT patients without higher rates of meaningful complications and overall very low transfusion rates regardless of AT status.

Third, regarding peri- and postoperative outcomes, no major differences between no AT and AT patients were recorded regarding operative time and catheter time in our analyses. This is conflicting with two other reports [13, 23] stating longer length of stay for AT patients and El Tayeb et al. [23] even stating a shorter operation time in patients taking AT. It is of note that in these reports, median length of stay was 1 day as opposed to 2 days, representing our institutional standard before catheter removal and discharge. Boeri et al. also affirmed a comparatively longer hospital stay and catheter maintenance, while they did not see any difference regarding operation time [25].

Interestingly, we observed a lower enucleation volume in the AT group, whereas operation time was comparable between the groups. This “volume effect” might be related to preferential use of HoLEP in patients with AT compared to TUR-P (patient selection). However, the lower enucleation volume

| Variable                      | Odds ratio | Confidence interval (2.5–97.5%) | p value |
|-------------------------------|------------|---------------------------------|---------|
| (A) Univariable predictors of complications |            |                                 |         |
| No AT                        | Ref        | –                               | –       |
| PAI                          | 1.5        | 0.7–2.8                         | 0.3     |
| NOACs                        | 1.5        | 0.5–4.1                         | 0.4     |
| LMWH/comb                    | 3.5        | 1.1–11.4                        | 0.03    |
| ASA I/II                     | Ref        | –                               | –       |
| ASA III/IV                   | 2.6        | 1.4–4.6                         | <0.01   |
| Age                          | 1.1        | 1.0–1.1                         | <0.01   |
| Operative time               | 1.0        | 1.0–1.0                         | 0.3     |
| No prostate carcinoma (PCa)  | Ref        | –                               | –       |
| Bioplastic or incidental PCa | 2.9        | 1.4–5.8                         | <0.01   |
| Prostate enucleation volume  | 1.0        | 1.0–1.0                         | 0.7     |
| (B) Multivariable predictors of complications |            |                                 |         |
| No AT                        | Ref        | –                               | –       |
| PAI                          | 0.8        | 0.3–1.7                         | 0.5     |
| NOACs                        | 0.7        | 0.2–2.0                         | 0.5     |
| LMWH/comb                    | 1.5        | 0.4–5.6                         | 0.6     |
| ASA I/II                     | Ref        | –                               | –       |
| ASA III/IV                   | 2.2        | 1.0–4.6                         | 0.04    |
| Age                          | 1.04       | 1.0–1.1                         | 0.02    |
| No PCa                       | 2.5        | 1.2–5.1                         | 0.01    |
| Bioplastic or incidental PCa |            |                                 |         |

PAI: platelet aggregation inhibitors, NOAC: new oral anticoagulants, LMWH/comb: low molecular weight heparins or combination of AT.
volume did not translate into significant differences in operative time or differences in efficacy of enucleation, as displayed by the velocity of tissue retrieval. Taken together, our institutional standard seems to offer a safe approach for patients with and without AT.

Forth, immediate postoperative assessment of maximum flow and residual urine after removal of the transurethral catheter invariably improved after HoLEP in each AT group. Due to sample size limitations, a significant effect could not consistently be confirmed in NOAC and LMWH/combination patients in each subanalysis. However, even in these small groups, the medians before and after HoLEP improved clinically meaningfully (maximum flow pre- vs. postoperatively 11.1 vs. 18.7 ml/s in NOACs and 9.6 vs. 14.0 ml/s in LMWH/combination and residual void urine 70 vs. 25 ml in NOACs and 125 vs. 60 ml in LMWH/combination). Moreover, proportion of successful postoperative voiding trial improved in all AT groups except for LMWH/combination patients. In this group proportion of successful postoperative voiding trial nevertheless clinically meaningfully improved (46.2 to 15.4%) despite not being statistically significant due to small sample size (6, respectively, 2 of 13). Similarly, IPSS at 3 months after surgery improved clinically meaningfully (pre- vs. postoperatively 18 vs. 6 in NOACs and 19 vs. 3 in LMWH/combination) despite not being statistically significant due to small sample size. It can be postulated that HoLEP in AT patients is equally effective as in no AT patients. Moreover, it is of note that several studies [26, 27] reported on ongoing improvements within the first 6 months after HoLEP and thus, these very early results at discharge will invariably be subject to further improvements.

Taken together, patients with AT represent a growing proportion of contemporary patients. The complication rate of HoLEP performed under AT did not differ according to AT status. HoLEP is a safe and effective technique for enucleation of the prostate in anticoagulated patients.

Conclusion

Despite higher minor complication rates in AT patients, major complications were not more frequent in AT patients. After adjustment for covariates as age and ASA status, complication rate did not differ according to AT status. HoLEP is a safe and effective technique for enucleation of the prostate in anticoagulated patients.

Acknowledgements Open Access funding provided by Projekt DEAL.

Author contributions MD: protocol/project development, data collection or management, data analysis, manuscript writing/editing. JR: protocol/project development, data collection or management, data analysis, manuscript writing/editing. PIK: manuscript editing. MW: data collection or management. LAK: data collection or management. SB: data collection or management. FCR: data collection or management. PM: data collection or management. FKHC: data collection or management, manuscript editing. AB: protocol/project development, data collection or management, manuscript editing.

Funding We did not receive any funding for our work.

Conflict of interest Our research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors report no potential conflicts of interest.

Availability of data and material The data is available for requests.

Code availability Not applicable.

Ethics approval Ethical approval was obtained from the local ethics committee at the University Hospital of Frankfurt.

Informed consent All included patients gave informed written consent.

Research involving human participants and/or animals Our Research involved Human participants.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kim EH, Larson JA, Andriole GL (2016) Management of benign prostatic hyperplasia. Annu Rev Med 67:137–151
2. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W et al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 42(4):323–328
3. De Wilde S, Carey IM, Emmas C, Richards N, Cook DG (2006) Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulants and predictors of such treatment in UK primary care. Heart 92(8):1064–1070
4. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC (2012) National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 5(5):615–621
5. Sindet-Pedersen C, Pallisgaard JL, Staerk L, Berger JS, Lamberts M, Torp-Pedersen C et al (2017) Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism—a Danish nationwide cohort study. Sci Rep 7(1):3347
6. Gratzele C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109
7. Parr NJ, Loh CS, Desmond AD (1989) Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br J Urol 64(6):623–625
8. Michalak J, Tzou D, Funk J (2015) HoLEP: the gold standard for the surgical management of BPH in the 21st century. Am J Clin Exp Urol 3(1):36–42
9. Rivera M, Krambeck A, Lingeman J (2017) Holmium laser enucleation of the prostate in patients requiring anticoagulation. Curr Urol Rep 18(10):77
10. Suardi N, Gallina A, Salonia A, Briganti A, Deho F, Zanni G et al (2009) Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. Curr Opin Urol 19(1):38–43
11. Gilling PJ, Cass CB, Cresswell MD, Fraundorfer MR (1996) Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia. Urology 47(1):48–51
12. Elzayat E, Habib E, Elhilali M (2006) Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 175(4):1428–1432
13. Bishop CV, Liddell H, Ischia J, Paul E, Appu S, Frydenberg M et al (2013) Holmium laser enucleation of the prostate: comparison of immediate postoperative outcomes in patients with and without antiarthromobic therapy. Curr Urol 7(1):28–33
14. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 230(2):205–213
15. Mitropoulos D, Artibani W, Briyanis C, Bjerggaard Jensen J, Roupret M, Truss M (2018) Validation of the Clavien–Dindo grading system in urology by the European Association of Urology guidelines ad hoc panel. Eur Urol Focus 4(4):608–613
16. Wastesson JW, Morin L, Tan ECK, Johnell K (2018) An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 17(12):1185–1196
17. Payne RA (2016) The epidemiology of polypharmacy. Clin Med (Lond) 16(5):465–469
18. Becker B, Netsch C, Hansen J, Bohnme A, Gross AJ, Zacharias M et al (2019) Perioperative safety in patient under oral anticoagulation during holmium laser enucleation of the prostate. J Endourol 33(3):219–224
19. Zheng X, Peng L, Cao D, Han X, Xu H, Yang L et al (2019) Holmium laser enucleation of the prostate in benign prostate hyperplasia patients with or without oral antithrombotic drugs: a meta-analysis. Int Urol Nephrol 51(12):2127–2136
20. Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR (2003) A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 170(4 Pt 1):1270–1274
21. Li S, Zeng XT, Ruan XL, Weng H, Liu TZ, Wang X et al (2014) Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis. PLoS ONE 9(7):e101615
22. Kunz RM, Ahyai S, Lehrich K, Fayad A (2004) Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol 172(3):1012–1016
23. El Tayeb MM, Jacob JM, Bhojani N, Bamberlin E, Lingeman JE (2016) Holmium laser enucleation of the prostate in patients requiring anticoagulation. J Endourol 30(7):805–809
24. Tyson MD, Lerner LB (2009) Safety of holmium laser enucleation of the prostate in anticoagulated patients. J Endourol 23(8):1343–1346
25. Boeri L, Capogrosso P, Ventimiglia E, Fontana M, Sappogna G, Zanetti SP et al. Clinical comparison of holmium laser enucleation of the prostate and bipolar transurethral enucleation of the prostate in patients under either anticoagulation or antiplatelet therapy. Eur Urol Focus. 2019.
26. Sun I, Yoo S, Park J, Cho SY, Jeong H, Son H et al (2019) Quality of life after photo-selective vaporization and holmium-laser enucleation of the prostate: 5-year outcomes. Sci Rep 9(1):8261
27. Alkan I, Ozveri H, Akin Y, Ipekci T, Ipekci A, Alcan Y (2016) Holmium laser enucleation of the prostate: surgical, functional, and quality-of-life outcomes upon extended follow-up. Int Braz J Urol 42(2):293–301

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.